GLP-1 agonists

Treatment Options for a Young, Newly Diagnosed Patient with a High BMI

Dr. Jack Leahy, endocrinologist and general internist, Dr. Doron Schneider, weigh different initial treatment options presented by leading endocrinologists Silvio Inzucchi, MD, Alan J. Garber, MD and Laurence Kennedy, MD

Listen to the podcast and/or read the transcript.

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Inzucchi, Silvio E; Bergenstal, Richard M; Buse, John B; Diamant, Michaela; Ferrannini, Ele; Nauck, Michael; Peters, Anne L; Tsapas, Apostolos; Wender, Richard; Matthews, David R
Diabetes care; 2012 Jun;35(6):1364-79. PMID: 22517736

A Newly Diagnosed Patient with a High BMI

A 38-year-old Caucasian male presents to your office reporting symptoms of fatigue, thirst, and weight loss. He has not been to a physician since his late 20s. Your physical examination shows high blood pressure (150/96 mmHg) and a BMI (body-mass index) of 36 kg/m2. There is a family history of cardiovascular disease, although the patient himself reports having no personal history of cardiac symptoms or cardiovascular events.

Who is the Right Patient for SGLT-2 Inhibitors?

Dr. Leahy’s comments are right-on target. Some further observations by another endocrinologist who can’t determine who the best patient for this new class of drugs will be:
1.     The advisory committee had problems with the bump in LDL-cholesterol. True, this is a surrogate, not a true “outcome” that will be determined in the CANVAS study. But do you recall the last time we had this debate with a diabetes drug?